A recent analysis of breast cancer samples integrated in The Cancer Genome Atlas (TCGA) revealed that KIF2C, along with two cell cycle master regulators CCNB1 (cyclin B1) and Plk1, is a promising target for breast cancer therapy [140]. This evidence concerns the gene PLK1 and breast carcinoma.